Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NPS 1776 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | PLACEBO |
| 2 | EXPERIMENTAL | 400 mg 1776 powder |
| 3 | EXPERIMENTAL | 1776 (800 mg) |
| Name | Type | Description |
|---|---|---|
| NPS 1776 (800 mg) | DRUG | NPS 1776 (800 mg) powder |
| PLACEBO | DRUG | Placebo in non-carbonated fruit flavored drink (150 ml) |
| NPS 1776 (400 mg) | DRUG | NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink |
Inclusion Criteria: 1. Diagnosis of migraine for at least a year prior to screening. 2. Experiences 2-10 migraine headaches per month (with at least 24 hours between episodes) and no more than 15 headache days per month in the 3 months prior to screening. 3. Ability and willingness to arrive at the...
NPS 1776 is an investigational small molecule developed for the acute treatment of migraine headaches. It was studied in a Phase 2 clinical trial in adults with migraine. NPS 1776 has not been approved for any indication and remains in clinical development.
NPS 1776 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda sponsored the Phase 2 clinical trial of NPS 1776 in migraine headaches.
NPS 1776 is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any use.
NPS 1776 has been studied in one completed Phase 2 trial, NCT00172094, titled Safety and Efficacy of NPS 1776 in the Acute Treatment of Migraine Headaches. The randomized, double-blind, placebo-controlled trial enrolled 189 participants in the United States.